$HNGE

Robinson Elliott sold 0 shares of HNGE (indirect holdings)

Robinson Elliott sold 0 indirectly-held shares of Hinge Health, Inc. (HNGE) across 3 trades over 2026-06-10 to 2026-06-12.

Original reporting
SEC EDGAR · Robinson Elliott
Published Jun 12, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Neutral
high confidence
Mentioned
$HNGE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

While insider Form 4s can matter, this one reports 0 shares sold and 0 shares held after the transaction, limiting interpretability for trading flows.

02

Market read

A director’s Form 4 is disclosed, but the reported transaction size is 0 shares, suggesting negligible immediate trading significance.

03

What to watch

Because the transaction value and price are not disclosed and the share count is 0, traders should avoid inferring bearishness from the headline alone.

Relevance 2/10Novelty 2/10Timing: Filed 2026-06-12 (SEC Form 4)

Background

The article is an SEC EDGAR Form 4 insider transaction filing for Hinge Health, Inc. (HNGE).

Company-level read

Ticker impact

$HNGENeutralHigh confidence
Context

Robinson Elliott (director) filed an SEC Form 4 showing open-market sale transactions totaling 0 shares and ending with 0 shares held.

Expected impact

Minimal to no price impact expected; any effect would be limited to signaling/positioning rather than a tradable flow.

Evidence & confidence

The filing explicitly reports 0 shares across trades and 0 shares after the transaction, with no disclosed price or value, reducing materiality.

Market effects

No clear sector read-through; this is a single-insider Form 4 with zero-share execution.

None indicated.

None indicated.

Counterpoint

The 0-share outcome could reflect administrative/technical entries (e.g., plan mechanics or cancellations), so it may not represent any real selling pressure.

Key entities

  • Hinge Health, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Robinson Elliott

    Director who reported the open-market sale transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Could Hinge Health (HNGE) Stock Win as Digital Healthcare Expands Beyond MSK Care?

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

$HNGEMedAI 8/10

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

$HNGEMed

Hinge Health (HNGE) Just Bought Its Way Into A New Market, So Now What?

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.